Radiotherapy Plus ADT Seen to Improve Survival in Advanced Prostate Cancers

Radiotherapy Plus ADT Seen to Improve Survival in Advanced Prostate Cancers
Combining prostate radiotherapy with standard-of-care androgen deprivation therapies (ADT) significantly prolongs survival in patients newly diagnosed with metastatic prostate cancer, according to a recent study at the University of Colorado School of Medicine. The study, "Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer," published in the Journal of Clinical Oncology, shows that radiotherapy plus ADT therapy nearly doubles survival rates, compared to ADT alone. Survival is known to be better in metastatic prostate cancer patients when their primary tumor is treated with prostatectomy, but this treatment is invasive and not accessible to all. Recently, prostate radiotherapy has emerged as an attractive treatment strategy for these patients, given its non-invasive administration and the wide range of candidates. Recent studies have also shown that prostate radiotherapy can be used in nonmetastatic prostate cancer (PC) patients to manage their tumors, and increases survival in men with lymph node-positive PC. To address the benefits of adding prostate radiotherapy to ADT, the researchers used the National Cancer Data Base to identify newly diagnosed advanced PC patients. Between 2004 to 2012, 6,382 men were treated with ADT, 534 of which also received prostate radiotherapy, accounting for 8.4 percent of the examined population. After a median follow-up of 5.1 years, patients who received radiotherapy in combination with ADT had a significantly higher overall survi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *